Advertisement
UK markets close in 3 hours 5 minutes
  • FTSE 100

    8,115.58
    +36.72 (+0.45%)
     
  • FTSE 250

    19,801.58
    +199.60 (+1.02%)
     
  • AIM

    754.71
    +1.59 (+0.21%)
     
  • GBP/EUR

    1.1668
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2508
    -0.0003 (-0.02%)
     
  • Bitcoin GBP

    51,434.73
    +266.82 (+0.52%)
     
  • CMC Crypto 200

    1,387.32
    -9.21 (-0.66%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.43
    +0.86 (+1.03%)
     
  • GOLD FUTURES

    2,355.30
    +12.80 (+0.55%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,047.63
    +130.35 (+0.73%)
     
  • CAC 40

    8,042.23
    +25.58 (+0.32%)
     

Oak Street Health's (NYSE:OSH) investors will be pleased with their impressive 138% return over the last year

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a lot more than 100%. For example, the Oak Street Health, Inc. (NYSE:OSH) share price has soared 138% in the last 1 year. Most would be very happy with that, especially in just one year! Also pleasing for shareholders was the 84% gain in the last three months. Note that businesses generally develop over the long term, so the returns over the last year might not reflect a long term trend.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

Check out our latest analysis for Oak Street Health

Because Oak Street Health made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

ADVERTISEMENT

In the last year Oak Street Health saw its revenue grow by 54%. That's well above most other pre-profit companies. And the share price has responded, gaining 138% as we previously mentioned. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

It's probably worth noting that the CEO is paid less than the median at similar sized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

Oak Street Health boasts a total shareholder return of 138% for the last year. And the share price momentum remains respectable, with a gain of 84% in the last three months. This suggests the company is continuing to win over new investors. It's always interesting to track share price performance over the longer term. But to understand Oak Street Health better, we need to consider many other factors. Take risks, for example - Oak Street Health has 4 warning signs (and 1 which is concerning) we think you should know about.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here